Access comprehensive financial analyses and make smarter investments - get the Manual of Investments on Amazon!

BSX

In Brief - Boston Scientific (BSX) Stock

Shares of Health Care sector company Boston Scientific moved 1.6% today, and are now trading at a price of $96.01. The Large-Cap stock's daily volume was 11,893,428 compared to its average volume of 9,719,490. The S&P 500 index returned a 1.0% performance.

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company is based in Marlborough and has 53,000 full time employees. Its market capitalization is $142,329,266,176.

31 analysts are following Boston Scientific and have set target prices ranging from $99.0 to $140.0 per share. On average, they have given the company a rating of buy. At today's prices, BSX is trading -23.79% away from its average analyst target price of $125.98 per share.

Over the last year, BSX's share price has increased by 6.6%, which represents a difference of -8.0% when compared to the S&P 500. The stock's 52 week high is $109.5 per share whereas its 52 week low is $85.98. With average free cash flows of $1.53 Billion that have been growing at an average rate of 16.1% over the last 5 years, Boston Scientific is in a position to continue its strong stock performance trend.

Date Reported Cash Flow from Operations ($ k) Capital expenditures ($ k) Free Cash Flow ($ k) YoY Growth (%)
2024 3,435,000 790,000 2,645,000 47.6
2023 2,503,000 711,000 1,792,000 91.04
2022 1,526,000 588,000 938,000 -28.72
2021 1,870,000 554,000 1,316,000 16.25
2020 1,508,000 376,000 1,132,000 -17.67
2019 1,836,000 461,000 1,375,000
The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

IN FOCUS